Labiotech recently asked several biotech experts the same question about tackling cancer, for a special newsletter to commemorate World Cancer Day on February 4. The 2023 theme is Close the…
For our special newsletter on cancer, Labiotech had the opportunity to put the same question to several biotech company experts. And while no one can know for sure what the future…
ImaginAb Inc., in collaboration with Memorial Sloan Kettering Cancer Center (MSK) and Melanoma Research Alliance (MRA), has launched an investigator-initiated phase II trial. It will explore the efficacy and safety…
ImaginAb Inc., which is focused on developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) imaging agent and radiopharmaceutical therapy (RPT) products, is starting a phase II clinical trial. The trial, PRETZCEL, which…
Precision oncology company, Parthenon Therapeutics, and ImaginAb Inc., a global biotech have entered into a multi-year, non-exclusive license and supply agreement. Under the agreement terms, Parthenon will use ImaginAb’s CD8…
The first patient has been dosed at the Macquarie University Hospital in Sydney as part of a clinical trial to evaluate whether a drug can predict patient response to immuno-oncology…